Has antihypoxic effect. By directly affecting cardiomyocytes and neurons of the brain, the drug optimizes their metabolism and function. The cytoprotective effect is due to an increase in the energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (enhancement of glycolysis and fat oxidation blockade).
Trimetazidine supports myocardial contractility, prevents the reduction of intracellular levels of adenosine triphosphate (ATP) and phosphocreatinine. In conditions of acidosis normalizes the functioning of ion channels of membranes, prevents the accumulation of calcium and sodium ions in cardiomyocytes, normalizes the intracellular content of potassium ions.
Reduces intracellular acidosis and increased phosphate content, due to myocardial ischemia and reperfusion. Prevents the damaging effect of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemia zone, prolongs the duration of the electrical potential, reduces the yield of creatine phosphokinase (CK) from cells and the severity of myocardial ischemic damage Trimetazidine reduces the frequency of angina attacks, reduces the need for nitrates, after 2 weeks of use increases exercise tolerance, and sharp fluctuations in blood pressure (BP) decrease. Reduces dizziness and noise in the ears of ischemic etiology. In vascular pathology, the eye restores the functional activity of the retina.